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An increasingly larger fraction of patients with hematological diseases are treated by
hematopoietic stem cells transplantation (HSCT) from HLA matched unrelated donors.
Polymorphisms of HLA genes represent a major barrier to HSCT because HLA-A, -B, -C
and DRB1 incompatibilities confer a higher risk of acute graft-versus-host disease (aGVHD)
and mortality. Although >22 million volunteer HLA-typed donors are available worldwide,
still a significant number of patients do not find a highly matched HSC donor. Because of the
large haplotypic diversity in HLA-B–C associations, incompatibilities occur most frequently
at HLA-C, so that unrelated donors with a single HLA-C mismatch often represent the only
possible choice.The ratio of HLA-C-mismatched HSCT over the total number of transplants
varies from 15 to 30%, as determined in 12 multicenter studies. Six multicenter studies
involving>1800 patients have reported a 21–43% increase in mortality risk. By using in vitro
cellular assays, a large heterogeneity in T-cell allorecognition has been observed. Yet the
permissiveness of individual HLA-C mismatches remains poorly defined. It could be linked
to the position and nature of the mismatched residues on HLA-C molecules, but also to vari-
ability in the expression levels of the mismatched alleles. The permissive C*03:03–03:04
mismatch is characterized by full compatibility at residues 9, 97, 99, 116, 152, 156, and
163 reported to be key positions influencing T-cell allorecognition. With a single difference
among these seven key residues the C*07:01–07:02 mismatch might also be considered
by analogy as permissive. High variability of HLA-C expression as determined by quanti-
tative RT-PCR has been observed within individual allotypes and shows some correlation
with A–B–C–DRB1 haplotypes. Thus in addition to the position of mismatched amino acid
residues, expression level of patient’s mismatched HLA-C allotype might influence T-cell
allorecognition, with patients low expression-C alleles representing possible permissive
mismatches.
Keywords: HLA-C polymorphism, stem cell transplantation, incompatibilities, permissive mismatches, clinical
outcome, HLA-C expression levels
INTRODUCTION
HLA compatibility is a crucial parameter that influences the clini-
cal outcome of hematopoietic stem cells transplantation (HSCT).
Whereas it is technically simple to assess genotypic HLA com-
patibility in a related HSCT setting, the situation becomes more
complex for unrelated donor selection. Here the developments in
HLA typing technology have significantly contributed to improve
the efficiency of unrelated HSC donor searches, resulting in a better
recipient–donor HLA matching and a better prognostic for clinical
outcome. In most transplant centers matching at HLA-A, -B, -C,
DRB1, and DQB1 loci, a so-called 10/10 match, is the gold stan-
dard for unrelated donor selections (1–3). Although single DQB1
mismatches appear to be better tolerated than mismatches at other
loci, they have an additive effect to A, B, C, DRB1 loci (1–4).
Historically, the recognition of HLA-C mismatches as bona fide
transplantation antigens occurred a few years after the demon-
stration of the relevance of HLA-A, -B, DRB1 mismatches (5–7),
because of the later developments in DNA-based analysis of HLA-
C allelic polymorphism. Among HLA class I incompatibilities, a
higher frequency of HLA-C compared to HLA-A, -B disparities
has been disclosed, thus conferring a higher statistical power to
the analysis of its role, possibly contributing to overestimate the
impact of C-mismatches relative to disparities at other HLA loci.
In any case large evidence points now to the clinical relevance of
including HLA-C matching in the donor search algorithm.
The key role of HLA-C molecules as ligands of killer
immunoglobulin-like receptors (KIRs) adds further complexity
to a fair evaluation of the impact of HLA-C incompatibilities in
HSCT. A large body of data pointing to the crucial role of HLA–
KIR interactions in controlling the antileukemic activity of donor
NK cells have been extensively reviewed elsewhere (8–10) and will
therefore not be addressed here.
OCCURRENCE AND CLINICAL RELEVANCE OF HLA-C
INCOMPATIBILITIES
Prospective and/or retrospective HLA typing of HSCT
donor/recipient pairs showed that HLA-C mismatches represent
40–50% of all HLA class I and II incompatibilities (DPB1 not
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being considered) (Table 1). As determined in 11 different cohorts,
a donor with a single HLA-C disparity had been selected in
13–31% of all transplants (Table 1). About 80% of HLA-C dis-
parities concerned antigen mismatches (11–13). Thus HLA-C
is by far the most frequent HLA mismatch, whereas the low-
est rate of mismatches is found at locus DRB1. This probably
reflects a more stringent priority given to DRB1 matching, less
advanced technology for HLA-A, -B high resolution typing in
clinical laboratories during the years 1990–2000, and more recent
application of HLA-C prospective typing in the donor search
algorithms (14).
Ten clinical studies including >100 patients have specifically
addressed the impact of HLA-C allele or antigen disparities and
they all report a deleterious role of C-mismatches. As summa-
rized in Table 2, six studies report a 20–100% increased risk of
acute GVHD (11, 13, 15, 16, 21, 24). Out of the 10 studies ana-
lyzing overall survival, 8 report a 21–94% statistically significant
increased mortality risk (11–13, 21, 24–26). Interestingly, the study
that did not observe any impact of C-mismatches (assigned by
retrospective typing) on survival concerns HSCT performed in
1993–1998 by the Japanese Marrow Donor Program (JMDP) (15).
When JMDP patients transplanted in a later period (2000–2009)
were analyzed the deleterious impact of C-mismatches became
significant (23).
The evaluation of the relative importance of HLA-C mis-
matches may be influenced by differences in the frequencies of
individual mismatches in different populations. For example,
the C*03:03–03:04 mismatch accounted for 68.7% of C allele







(15) 156/412 (37.8) 156/973 (16) 1993–1998








(18) 34/74 (45.9) 34/144 (23.6) 1994–2003
(19) 29/69 (42) 29/214 (13.6) 1990–2003
(20) 91/187 (48.6) 91/334 (27) 1993–2003
(21) 478/985 (48.5) 478/2825 (16.9) 1988–2003
(22) – 419/1361 (31)
(11) 250/498 (50.2)d 250/1741 (14.4) 1999–2006
(12) 634/1524 (41.6) 634/2646 (24) 1997–2010
(23) 524/1037 (50.5) 524/3003 (17.4) 1993–2009
(24) 1016/2031 (50)d – 1988–2009
(13) 895/1854 (48.3)d 895/6633 (13.5) 1988–2009
aNumber (nb) of patient/donor combinations with a single HLA-C mismatch
(MM)/total nb of mismatches for HLA-A, -B, -C, DRB1, DQB1 loci.
bNumber (nb) of patient/donor combinations with a HLA-C mismatch (MM)/total
nb of patients.
cTime-frame of the HSCT included in the study (TX: transplantation).
dOnly 7/8 matched donors with single class I MM were considered.
disparities in the recent CIBMTR study (13), but only 44.4% of
the allele disparities detected in the JMDP study (28).
Furthermore, the relevance HLA-C allele versus antigen mis-
matches (11, 13, 21) may be biased by the nature of individual
mismatches. Very few data are available concerning the relative
frequencies of individual C-mismatches (13, 28, 29). Because of
the very different HLA haplotypes in the Japanese population a
significant fraction of the C-mismatches will not be encountered
in patients of European ancestry. For example, allele mismatches
within the C*07 allotype occur more frequently in patients cohorts
of European ancestry, when compared to the JMDP study (28).
As determined in the IHWS HSCT cohort C*03:03–03:04 mis-
matches accounted for 21/257 (8.2%) and 12/82 (14.6%) single
(antigen and allele) HLA-C disparities, in JMDP and, respectively,
non-JMDP patients (28). Of 257 HLA-C mismatched pairs iden-
tified in the non-JMDP patients, 172 (70%) were not found in
the JMDP patient/donor pairs. Therefore the nature of individual
mismatches strikingly differs in European and Asian populations.
RELATIVE IMPORTANCE OF INDIVIDUAL HLA-C
MISMATCHES
In a first attempt from the JMDP to disclose individual HLA-
C mismatches with higher clinical relevance, seven HLA-C allele
mismatched combinations were reported to confer a higher risk of
acute GVHD (29). Four amino acid residues at positions 9, 99, 116,
and 156 of HLA-C molecules were significantly associated with
acute graft-versus-host disease (aGVHD). A subsequent JMDP
study showed that four specific HLA-C mismatches, C*01:02–
14:02, C*08:01–01:02, C*14:02–03:04, and C*15:02–14:02 were
associated with a lower risk of relapse (30), the latter being among
the ones reported previously to confer a higher aGVHD risk (29).
New insights on the role of specific residues of HLA molecules
in peptide-binding and TCR recognition (31) allowed a much
better understanding of the T-cell alloreactive response to mis-
matched HLA antigens. The concept that specific residues could
be essential in allorecognition led to a few clinical studies aimed
at demonstrating the predominant role of discrete parts of the
incompatible HLA molecules in clinical outcome (24, 32, 33).
Using a random forest statistical analysis 13 amino acid (aa)
substitutions in the HLA class I peptide-binding pocket have been
reported to be associated with increased mortality at day 100 in
low/intermediate risk patients transplanted with HSC from a sin-
gle HLA class I mismatched donor, with positions 9, 99, 116, and
156 being the most clinically relevant (33). HLA-C mismatch at
position 99 was reported to be associated with increased TRM and
a C-mismatch at position 116 with increased risk of acute GVHD.
When comparing individual C-mismatches at seven key
residues in the peptide-binding site (PBS) that have been
reported to be non-permissive substitutions marked differences
are observed (Table 3). Strikingly, two of the most frequent mis-
matches exhibit no (C*03:03–03:04) or only one (C*07:01–07:02)
amino acid (aa) difference at positions 9, 97, 99, 116, 152, 156,
and 163, whereas all other common mismatches include a substi-
tution at 3–6 positions. Whether this difference may allow clas-
sifying HLA-C incompatibilities as permissive/non-permissive,
remains to be confirmed. It is however relevant to note that
the C*03:03–03:04 mismatch did result in a negative or weakly
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Table 2 | Hazard ratios for two outcomes in nine HSCT cohorts with single HLA-C mismatches.
Reference Nb pat TCD/RIC YearTX Nb aGVHDa OS
C-MM HR (95% CI) HR (95% CI)
(15) 1288 No TCD 1993–1998 156/272b 1.85 (1.42–2.41) p<0.001 No impact
(17) 948 No TCD 1985–2003 24c – 3.18 (1.74–5.82)
61 – 1.32 (0.95–1.84)
(16) 1874 – 1988–1996 749 1.19 (1–1.41) p=0.05 1.21 (1.06–1.38) p=0.005
(25) 114 (CML) 32% TCD 1988–1999 24 – 1.94 (1.0–3.9) p=0.06
(26) 111 100% RIC 2000–2004 33 – 1.85 p=0.04
(21) 2825 36% TCD 1988–2003 382 1.6 (1.33–1.93) p<0.001 1.22 (1.06–1.39) p=0.004
No RIC
(11) 1933 35% RIC 1992–2006 168/189d 1.98 (1.5–2.62) p<0.001 1.41 (1.16–1.70) p=0.005
No TCD Grade III–IV
(12) 3035 No TCD 1997–2010 620 – 1.35 (1.17–1.56) p<0.001
36% RIC
(23) 751 No TCD/RIC 1993–1999 124 2.02 (1.27–3.20) p=0.0029 0.96 (0.73–1.26) p=0.77
2252 2000–2009 386 1.51 (1.12–2.02) p=0.0067 1.35 (1.15–1.59) p=0.0003
Grade III–IV
(13) 6633 22% RIC 1988–2009 700e 1.72 (1.11–2.69) p=0.02 1.43 (1.06–1.92) p=0.02
aGrade II–IV except for Ref. (16, 23).
bC-mismatches and aGVHD risk: 156 single MM, 272 multiple MM.
cSingle C-MM, low risk disease: 24 patients, high/intermediate risk disease: 61 patients.
dAntigen MM only (64 allele MM have no impact on GVHD/OS), 168 C-MM (aGVHD), 189 C-MM (OS).
eAntigen MM.
TCD, T-cell depletion; RIC, reduced intensity conditioning.
Table 3 | Substitutions in the peptide-binding site (PBS) associated with outcome (3, 24, 32) in 13 frequent HLA-C mismatches as reported in
Ref. (28).
HLA-C MM Nb pata Residues in the PBS Nb
9 97 99 116 152 156 163 MMb
03:03–03:04 22 – – – – – – – 0
07:01–07:02 14 – – Y/S – – – – 1
15:02–14:02 13 Y/S R/W Y/F L/S – L/R – 5
04:01–16:01 10 S/Y R/W F/Y F/S E/A R/Q – 6
01:02–02:02 9 F/Y W/R C/Y Y/S – R/W – 5
05:01–07:04 8 Y/D – – – E/A R/D – 4
07:02–03:04 8 D/Y – S/Y S/Y A/E – T/L 5
14:02–01:02 7 S/F – F/C S/Y – – – 3
12:03–07:01 9 Y/D – W/R – E/A W/L – 4
02:02–15:02 7 – – – S/L – W/L E/T 3
12:03–04:01 5 Y/S W/R Y/F S/F – W/R – 6
03:04–04:01 5 Y/S – Y/F – – L/R L/T 4
01:02–15:02 5 F/Y W/R C/Y Y/L – R/L – 5
aNumber of patient/donor pairs.
bNumber of mismatched residues in the PBS (out of the seven key amino acids reported to be associated with outcome).
positive CTL-precursor frequency (CTLpf) analysis (34, 35), and
was therefore considered as a potential permissive mismatch. This
is supported by a recent large scale study showing that 7/8 matched
HSCT patients with a single C*03:03–03:04 mismatch had the
same outcome as compared to 8/8 matched patients (13). On the
other hand, two of the most frequent C-disparities differed by 5–
6 key residues in the peptide-binding pocket: the C*15:02–14:02
mismatch in B51-positive patients and the C*04:01–12:03 mis-
match in B35-positive patients. It is tempting to suggest that such
mismatches could be considered as non-permissive.
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RECOGNITION OF HLA-C INCOMPATIBILITIES BY
ALLOREACTIVE T CELLS
In a first small scale study combining DNA typing and in vitro
cellular assays such as the CTLpf analysis, the results suggested
that HLA-C incompatibilities that were negative in an in vitro
CTLpf assay may be of lower clinical relevance (5). It is well docu-
mented that single HLA class I allele mismatches, including HLA-C
disparities, are efficiently recognized by CTLs (7, 35–42).
Based on CTLpf analysis of donor/recipient pairs with a single
HLA-C incompatibility, alloreactivity was reported to be influ-
enced by the number and position of the mismatched residues in
the PBS (39). Negative CTLpf assays occurred more frequently in
pairs with>9 aa differences compared to pairs with 0–5 aa differ-
ences in the α-helices and β-sheet. A model to predict cytotoxic
T-cell alloreactivity was based on an amino acid mismatch score
depending on the position and physicochemical properties of the
mismatched residues (40). After testing the model on 171 9/10 and
168 10/10 matched HSCT patients, these authors found out that
the aa mismatch score did not predict clinical outcome (41).
Infection- and vaccine-induced memory T cells have a high
cross-reactive potential against allo-MHC molecules (43). Substi-
tutions at key residues in the PBS (Table 3) are expected to modify
the endogenous peptide repertoire bound to allo-HLA molecules,
thereby increasing the cross-reactive potential of virus-specific
memory T cells. Possibly multiple substitutions of key residues
in the PBS (e.g., C*03:04–07:02) may increase the number of
cognate ligands recognized by alloreactive T-cells (structural mim-
icry), as compared to mismatches with a single substitution such as
C*07:01–07:02. Accurate modeling of peptide–HLA interactions
(44) allowing to point to high risk non-permissive substitutions
should contribute to a better evaluation of the permissiveness of
HLA class I mismatched residues.
HLA-C EXPRESSION LEVEL AND ALLOREACTIVITY
In the last couple of years, several studies have pointed to variabil-
ity in HLA-C expression levels, as analyzed by RT-PCR and by DT9
antibody binding in heterozygous individuals. Such variability was
shown to correlate with the antiviral response in HIV+ patients
(45, 46). The association with HIV disease outcome was origi-
nally reported to be linked to a dimorphism at −35 kb upstream
the HLA-C gene (27, 45). Subsequently, HLA-C expression was
reported to be determined by a microRNA binding site dimor-
phism (263 indel) in the 3′UT region of HLA-C (47), and most
recently by a MIR148A polymorphism affecting the microRNA
miR-148a own expression and consequently the level of HLA-
C expression in individuals carrying an intact miR-148a binding
site (48).
Although the determination of HLA-C by DT9 antibody stain-
ing has the advantage to reflect bona fide cell surface expression
it does not allow to dissect haplotype-dependant expression levels
because the large majority of individuals are heterozygous. Even
homozygous donors might show different HLA-C expressions lev-
els that would depend on the extended ABDR haplotypes. This
may account for apparent differences in expression levels reported
previously. For example, HLA-C*07:02-positive (heterozygous)
individuals were first classified among those with high expres-
sion allotypes (45), whereas it is found among the low expression
allotypes in a study on African-American patients (46). Apparent
inconsistencies are also noted when HLA-C allotypes were clas-
sified with high or low expression as based on DT9 antibody
binding or on polymorphism in the 3′UTR miR-148 binding site.
For example C*01:02 and C*04:01 are classified as low expres-
sion alleles based on the 3′UTR miR-148 binding site, but as
high expression alleles based on DT9 binding. C*05:01 is clas-
sified as a high expression allele based on 3′UTR 263 indel, but
is reported as low/intermediate based on DT9 binding. We have
recently reported some evidence that HLA-C alleles can not be
simply classified as high/low expression alleles, because significant
interindividual variability was disclosed, at least for the C*03:04,
C*04:01, C*05:01, or C*06:02 allotypes (49). Relevant correla-
tion was found between HLA-C mRNA expression levels and the
extended HLA-A, -B, DRB1 haplotypes. Under the hypothesis
that differences in the level of expression might directly influ-
ence the CTL response, a simple test for quantifying allele-specific
anti-HLA-C alloreactive T-cell responses or, indirectly, HLA-C
recipient allotype expression levels, would help in donor selec-
tion and risk assessment before HSCT. Because HLA-C expression
levels may impact both positive and negative thymic selection in
the donor it is difficult to predict how this would translate in the
donor T cell-mediated alloresponse against mismatched HLA-C
antigens.
In summary, clinical studies point to a negative impact of single
HLA-C mismatches in unrelated HSCT, with a 21–43% increased
mortality risk. In the vast majority of the transplant centers unre-
lated donor search algorithms now take HLA-C compatibility into
account. However, the diversity of HLA–B–C associations in spe-
cific haplotypes results in a rather high rate of HLA-C mismatches.
The strength of the immune responses to HLA-C disparities may
vary in different patient/donor combinations. HLA-C allorecogni-
tion will be impacted by the position of the mismatched residues
on the HLA molecule, by the level of expression of the targeted
mismatched allotype, and by the T-cell repertoire of the donor,
which is modulated by the infectious history of each individual.
Possible permissive mismatches may be assigned when no or very
few substitutions occur at the key positions 9, 97, 99, 116, 152, 156,
and 163 in the peptide-binding pocket, or in cases of low expres-
sion mismatched alleles, such as C*07:01/02 alleles. By analogy
to findings concerning HLA-B incompatibilities (50), it may be
anticipated that HLA-C disparities that involve residue(s) in the
α3-domain (such as the C*02:02–02:29 mismatch) may be con-
sidered as permissive mismatches. This remains however to be
demonstrated by functional in vitro assays, until clinical studies
become large enough to provide sufficient statistical power for
an analysis of α3-domain disparities. A better definition of such
mismatches is required to increase the pool of acceptable donors,
particularly for patients with rare HLA-B–C haplotypes.
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